Skip to main
MMSI

MMSI Stock Forecast & Price Target

MMSI Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 56%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Merit Medical Systems Inc. is witnessing a positive financial trajectory, with gross margins expanding significantly from 48.8% in FY22 to an estimated 53.4% by 2025, reflecting improved operational efficiency. The company's overall revenue has grown approximately 11%, supported by a robust 11% increase in its Cardiovascular segment, which continues to be the primary revenue driver, bolstered by increased physician reimbursement rates that may enhance product adoption. Additionally, the Endoscopy segment has demonstrated strong performance, with revenues reaching $20.1 million and marking a 15% growth, indicating a favorable trend towards increased procedure volumes and pricing advantages.

Bears say

Merit Medical Systems has faced notable challenges in its revenue growth, particularly with OEM revenue falling short of expectations at $48.1 million compared to the anticipated $58.3 million. Critical risks include worse-than-expected margin performance, free cash flow issues, and slowed growth in key markets like China, which has shown a decline in revenue due to value-based purchasing headwinds and macroeconomic pressures. The company's bear case scenario suggests a revenue growth rate of 5% or lower, driven by poor performance from recent acquisitions and new product launches, potentially leading to further operating margin contraction and earnings falling below consensus estimates.

MMSI has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merit Medical Systems and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merit Medical Systems (MMSI) Forecast

Analysts have given MMSI a Buy based on their latest research and market trends.

According to 9 analysts, MMSI has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $103.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $103.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merit Medical Systems (MMSI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.